X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (19) 19
index medicus (16) 16
middle aged (14) 14
male (13) 13
aged (12) 12
female (12) 12
hematology (11) 11
adult (8) 8
cancer (7) 7
chemotherapy (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
doxorubicin - therapeutic use (6) 6
oncology (6) 6
abridged index medicus (5) 5
cyclophosphamide - therapeutic use (5) 5
disease-free survival (5) 5
hemic and lymphatic diseases (5) 5
lymphomas (5) 5
non-hodgkins-lymphoma (5) 5
prednisone - therapeutic use (5) 5
rituximab (5) 5
vincristine - therapeutic use (5) 5
cyclophosphamide (4) 4
follow-up studies (4) 4
life sciences (4) 4
medicine, general & internal (4) 4
retrospective studies (4) 4
therapy (4) 4
1st-line treatment (3) 3
[ sdv.can ] life sciences [q-bio]/cancer (3) 3
[sdv.can]life sciences [q-bio]/cancer (3) 3
aged, 80 and over (3) 3
antibodies, monoclonal, murine-derived - therapeutic use (3) 3
b-cell lymphoma (3) 3
care and treatment (3) 3
hematology, oncology and palliative medicine (3) 3
lymphoma, large b-cell, diffuse - drug therapy (3) 3
phase-ii (3) 3
plus rituximab (3) 3
survival (3) 3
survival analysis (3) 3
transplantation (3) 3
young adult (3) 3
acute myeloid-leukemia (2) 2
aggressive lymphoma (2) 2
antibodies, monoclonal (2) 2
antibodies, monoclonal - adverse effects (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
cancer therapies (2) 2
clinical trials (2) 2
combination (2) 2
combined modality therapy (2) 2
cyclophosphamide - adverse effects (2) 2
diagnosis (2) 2
disease (2) 2
doxorubicin - adverse effects (2) 2
drug therapy (2) 2
elderly-patients (2) 2
expression (2) 2
fludarabine (2) 2
follow-up (2) 2
free survival (2) 2
hodgkin disease - pathology (2) 2
immunologic factors - therapeutic use (2) 2
immunosuppressive agents - administration & dosage (2) 2
immunosuppressive agents - adverse effects (2) 2
indolent (2) 2
internal medicine (2) 2
leukemia (2) 2
lymphoma (2) 2
lymphoma, b-cell - drug therapy (2) 2
lymphoma, follicular - drug therapy (2) 2
lymphoma, large b-cell, diffuse - mortality (2) 2
lymphoma, mantle-cell - drug therapy (2) 2
lymphoma, t-cell - drug therapy (2) 2
lymphoma, t-cell - mortality (2) 2
lymphoma, t-cell - pathology (2) 2
maintenance (2) 2
mortality (2) 2
multicenter (2) 2
multiple myeloma - complications (2) 2
neoplasm staging (2) 2
observational study (2) 2
prednisone (2) 2
prednisone - adverse effects (2) 2
prognosis (2) 2
research (2) 2
research article (2) 2
risk (2) 2
stem cells (2) 2
survival rate (2) 2
thalidomide - adverse effects (2) 2
treatment outcome (2) 2
vincristine - adverse effects (2) 2
2nd malignancies (1) 1
4100 (1) 1
[ sdv.bbm ] life sciences [q-bio]/biochemistry, molecular biology (1) 1
[ sdv.mp ] life sciences [q-bio]/microbiology and parasitology (1) 1
[sdv.can] life sciences [q-bio]/cancer (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10044, pp. 565 - 575
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9759, pp. 42 - 51
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2002, Volume 346, Issue 4, pp. 235 - 242
Journal Article
Haematologica, ISSN 0390-6078, 10/2012, Volume 97, Issue 10, pp. 1594 - 1602
Background In angioimmunoblastic T-cell lymphoma, symptoms linked to B-lymphocyte activation are common, and variable numbers of CD20(+) large B-blasts, often... 
Angioimmunoblastic t-cell lymphoma | Epstein-barr virus | Chop-r | VIRAL LOAD | MULTICENTER | angioimmunoblastic T-cell lymphoma | FOLLICULAR HELPER-CELL | NON-HODGKINS-LYMPHOMAS | PERIPHERAL-BLOOD | REARRANGEMENTS | PREDNISONE | POLYMERASE-CHAIN-REACTION | Epstein-Barr virus | CHOP-R | HEMATOLOGY | EXPRESSION | EPSTEIN-BARR-VIRUS | Doxorubicin - therapeutic use | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Immunoblastic Lymphadenopathy - mortality | B-Lymphocytes - virology | Female | Immunoblastic Lymphadenopathy - pathology | B-Lymphocytes - pathology | Prednisone - adverse effects | Rituximab | Immunoblastic Lymphadenopathy - drug therapy | Treatment Outcome | B-Lymphocytes - drug effects | Lymphoma, T-Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, T-Cell - pathology | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Lymphoma, T-Cell - mortality | Antibodies, Monoclonal, Murine-Derived - pharmacology | Neoplasm Staging | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Original and Brief Reports
Journal Article
Journal Article
Haematologica, ISSN 0390-6078, 05/2014, Volume 99, Issue 5, pp. 802 - 810
Journal Article
Journal Article
Journal Article